Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
Studies in gastroesophageal and locally advanced rectal cancers linked dynamic ctDNA monitoring to treatment response and prognosis. MRD clearance, more than 90% ctDNA declines, and early ctDNA clearance were associated with better outcomes.
Allogene Therapeutics said it will present interim futility analysis data from the Phase 2 ALPHA3 trial of cema-cel in first-line consolidation LBCL on April 13, 2026. The readout will assess day-45 MRD clearance in 12 patients per arm randomized to cema-cel or observation.
The FDA has approved Bristol Myers Squibb's CAR-T therapy Breyanzi for relapsed/refractory marginal zone lymphoma, while a novel multiple myeloma drug candidate DTP3 advances to Phase 2 trials after showing promising early results. Both developments represent significant progress in blood cancer treatment, with the marginal zone lymphoma approval based on a 95.5% response rate and the myeloma drug demonstrating selective cancer cell killing without toxicity.
Colorectal cancer diagnoses in people under 50 now account for nearly half of all new cases, prompting specialized treatment programs that use precision medicine and liquid biopsy technology to customize care based on individual tumor genetics.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
New research highlights circulating tumor DNA as a prognostic tool in early-stage triple-negative breast cancer, while leronlimab demonstrates long-term survival signals in heavily pretreated metastatic patients through CCR5 receptor blockade.
Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
Liquid biopsy-based circulating tumour DNA analysis has evolved from single-gene testing to comprehensive genomic profiling, enabling detection of actionable targets and minimal residual disease in colorectal cancer patients.
Ultrasensitive testing of tumor DNA in blood and urine may identify muscle-invasive bladder cancer patients who can safely forgo radical cystectomy, with 69% achieving 3-year bladder-intact survival after systemic therapy.
